Publication: Use of the Controlled Adverse Environment (CAE) in Clinical Research: A Review
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Springer Healthcare
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Ousler, George W., David Rimmer, Lisa M. Smith, and Mark B. Abelson. 2017. “Use of the Controlled Adverse Environment (CAE) in Clinical Research: A Review.” Ophthalmology and Therapy 6 (2): 263-276. doi:10.1007/s40123-017-0110-x. http://dx.doi.org/10.1007/s40123-017-0110-x.
Research Data
Abstract
The many internal and external factors that contribute to the pathophysiology of dry eye disease (DED) create a difficult milieu for its study and complicate its clinical diagnosis and treatment. The controlled adverse environment (CAE®) model has been developed to minimize the variability that arises from exogenous factors and to exacerbate the signs and symptoms of DED by stressing the ocular surface in a safe, standardized, controlled, and reproducible manner. By integrating sensitive, specific, and clinically relevant endpoints, the CAE has proven to be a unique and adaptable model for both identifying study-specific patient populations with modifiable signs and symptoms, and for tailoring the evaluation of interventions in clinical research studies.
Description
Other Available Sources
Keywords
Aqueous-deficient dry eye, Clinical trials, Controlled adverse environment, Disease models, Drug screening, Dry eye disease, Efficacy endpoints, Evaporative dry eye, Keratitis, Ocular discomfort, Tear film break up, Tear film deficiency
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service